ACROBiosystems社 Comprehensive ADC target
|Comprehensive ADC target.
|Antibody Drug Conjugates (ADCs) is a new class of biopharmaceutical drugs designed as a targeted therapy. ADCs deliver the chemotherapy via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.
TROP-2 is over-expressed in the majority of human epithelial cancers, including human colorectal, pancreatic, lung, oesophageal, oral, breast, uterine, glioma, and ovarian cancers and thus TROP-2 has become an attractive immunotherapeutic target in various cancer treatment.
Nectin-4 is overexpressed in several solid tumors, including urothelial, breast, gastric, and lung carcinomas. Enfortumab vedotin (PADCEV®) is the first FDA-approved Nectin-4-directed ADC for the treatment of metastatic urothelial carcinoma. Showing good potential in ADCs, Nectin-4 is a popular target for ADCs drug development.
LIV-1 is an estrogen-inducible gene. Its expression is associated with node-positivity in breast cancer; and has been detected in a variety of cancer types. Merck & Co and Seattle Genetics have signed an licensing to develop ladiratuzumab vedotin an investigational ADC targeting LIV-1.
Receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein expressed on several tumor types, has been considered to be a powerful anti-cancer potential target protein which likes PD-1. In addition, with the development of other ROR1-directed ADC, such as NBE-002 and LCB71, ROR1 has become a high-potential ADC target for multiple solid and hematological malignancies.
The purity of Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) was more than 85% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
>>High bioactivity validated by ELISA &BLI
Immobilized Human LIV-1,
Loaded Mouse Nectin-4, Fc Tag (Cat. No. NE4-M5257) on Protein A Biosensor, can bind Human Nectin-1, His Tag (Cat. No. PV1-H5223) with an affinity constant of 278 nM as determined in BLI assay (ForteBio Octet Red96e)
Loaded Anti-Human ROR1
Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。